Anacor Pharmaceuticals, Inc. (ANAC)
-NasdaqGM | Prev Close: | 5.66 |
|---|
| Open: | N/A |
|---|
| Bid: | 3.85 x 1000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.67 |
|---|
| Beta: | 1.69 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.00 - 8.25 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 652,900 |
|---|
| Market Cap: | 229.20M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.70 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ANACOR PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Anacor Pharmaceuticals: Should Retail Follow Institutions On This Biotech?at Seeking Alpha(Tue, May 14)
- Wider-Than-Expected Loss at AnacorZacks(Mon, May 13)
- Anacor Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- ANACOR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Anacor Pharmaceuticals Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu, May 9)
- Anacor Pharmaceuticals Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu, May 9)
- ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Thu, May 9)
- Q1 2013 Anacor Pharmaceuticals Inc Earnings Release - After Market CloseCCBN(Thu, May 9)
- Anacor Pharmaceuticals Announces First Quarter 2013 Financial Results Conference Call and WebcastBusiness Wire(Tue, May 7)
- Valeant Pharmaceuticals Provides Efinconazole UpdateCNW Group(Thu, May 2)
- Valeant Pharmaceuticals Provides Efinconazole UpdatePR Newswire(Thu, May 2)
- Anacor Pharmaceuticals Provides Update Regarding Arbitration With Valeant PharmaceuticalsBusiness Wire(Thu, May 2)
- ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Over-Allotment OptionBusiness Wire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 22.85 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.59 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | 0.25 |
|---|
Business Summary
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
View More 
0.12%